DE3875025D1 - Calcitonin enthaltende zusammensetzung fuer die nasale verabreichung. - Google Patents

Calcitonin enthaltende zusammensetzung fuer die nasale verabreichung.

Info

Publication number
DE3875025D1
DE3875025D1 DE8888401904T DE3875025T DE3875025D1 DE 3875025 D1 DE3875025 D1 DE 3875025D1 DE 8888401904 T DE8888401904 T DE 8888401904T DE 3875025 T DE3875025 T DE 3875025T DE 3875025 D1 DE3875025 D1 DE 3875025D1
Authority
DE
Germany
Prior art keywords
composition containing
nasal administration
containing calcitonin
calcitonin
nasal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8888401904T
Other languages
English (en)
Other versions
DE3875025T2 (de
Inventor
Nakayuki Yamamoto
Hideo Sakakibara
Kimio Mizuno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toyo Jozo KK
Original Assignee
Toyo Jozo KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP63144704A external-priority patent/JPH02111A/ja
Application filed by Toyo Jozo KK filed Critical Toyo Jozo KK
Publication of DE3875025D1 publication Critical patent/DE3875025D1/de
Application granted granted Critical
Publication of DE3875025T2 publication Critical patent/DE3875025T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE8888401904T 1987-08-03 1988-07-22 Calcitonin enthaltende zusammensetzung fuer die nasale verabreichung. Expired - Fee Related DE3875025T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP19265887 1987-08-03
JP29605987 1987-11-26
JP63144704A JPH02111A (ja) 1987-08-03 1988-06-14 経鼻投与用生理活性ペプチド製剤

Publications (2)

Publication Number Publication Date
DE3875025D1 true DE3875025D1 (de) 1992-11-05
DE3875025T2 DE3875025T2 (de) 1993-06-24

Family

ID=27318857

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8888401904T Expired - Fee Related DE3875025T2 (de) 1987-08-03 1988-07-22 Calcitonin enthaltende zusammensetzung fuer die nasale verabreichung.

Country Status (4)

Country Link
US (1) US5059587A (de)
EP (1) EP0302772B1 (de)
KR (1) KR890003400A (de)
DE (1) DE3875025T2 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE99543T1 (de) * 1987-10-15 1994-01-15 Syntex Inc Pulverfoermige zubereitungen zur intranasalen verabreichung von polypeptiden.
WO1990009781A1 (en) * 1989-02-23 1990-09-07 Rorer International (Holdings), Inc. Therapeutic aerosol formulations
IE64738B1 (en) * 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
US5384132A (en) * 1990-03-20 1995-01-24 Akzo N.V. Stabilized gonadotropin containing preparations
US5270057A (en) * 1990-03-20 1993-12-14 Akzo N.V. Stabilized gonadotropin containing preparations
GB9012663D0 (en) * 1990-06-07 1990-08-01 Erba Carlo Spa Galenic formulations containing cyclodextrins
IT1248725B (it) * 1990-06-12 1995-01-26 Sclavo Spa Composizione farmaceutica in polvere per somministrazione per via nasale contenente essenzialmente calcitonina ed un eccipiente idrosolubile
NL9002008A (nl) 1990-09-12 1992-04-01 Stichting Centr Diergeneeskund Recombinant dna en rna en daarvan afgeleide produkten.
GB9020544D0 (en) * 1990-09-20 1990-10-31 Sandoz Ltd Improvements in or relating to organic compounds
JP3179538B2 (ja) * 1990-12-11 2001-06-25 ノバルティス アクチエンゲゼルシャフト 安定なヒトカルシトニンの水性溶液
CA2070061C (en) * 1991-06-07 2004-02-10 Shigeyuki Takama Physiologically active polypeptide-containing pharmaceutical composition
JP3090353B2 (ja) * 1991-09-17 2000-09-18 旭化成工業株式会社 パラチロイドホルモン類含有経鼻投与用乳剤
US5571788A (en) * 1991-12-09 1996-11-05 Ciba-Geigy Corporation Stable calcitonin pharmaceutical compositions
WO1994007514A1 (en) * 1992-09-29 1994-04-14 Inhale Therapeutic Systems Pulmonary delivery of active fragments of parathyroid hormone
US5496801A (en) * 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
EP1462096B1 (de) * 1994-03-07 2008-12-10 Nektar Therapeutics Verfahren und Zusammensetzung für die pulmonale Darreichung von Insulin
US5652216A (en) * 1994-05-26 1997-07-29 Novo Nordisk A/S Pharmaceutical preparation
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
AU703532B2 (en) * 1994-12-22 1999-03-25 Astra Aktiebolag Therapeutic preparation for inhalation containing parathyroid hormone, PTH
DE726075T1 (de) * 1995-02-08 1996-12-12 Therapicon Srl Nicht-inorganische pharmazeutische salzige Lösungen zur endonasale Verabreichung
US5612053A (en) 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US5879712A (en) * 1995-06-07 1999-03-09 Sri International Method for producing drug-loaded microparticles and an ICAM-1 dosage form so produced
KR970032844A (ko) * 1995-12-29 1997-07-22 김준웅 지속성 경비투여제제
US6274553B1 (en) * 1997-01-20 2001-08-14 Japan Energy Corporation Method for stabilizing peptides and freeze-dried medicinal compositions containing peptides obtained by using the method
SE9702401D0 (sv) * 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
US6770623B1 (en) 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
MY120063A (en) * 1997-12-09 2005-08-30 Lilly Co Eli Stabilized teriparatide solutions
JP2003501404A (ja) 1999-06-04 2003-01-14 デルルックス ファーマシューティカル コーポレイション 薬剤の脱水粒子からなる製剤およびこれの調製方法
NZ518401A (en) * 1999-10-29 2004-01-30 Nektar Therapeutics Dry powder compositions having improved dispersivity
CA2399505C (en) 2000-02-04 2012-01-03 Unigene Laboratories, Inc. Nasal calcitonin formulations
US20090281023A9 (en) * 2001-06-04 2009-11-12 Nobex Corporation Mixtures Of Calcitonin Drug-Oligomer Conjugates And Methods Of Use In Pain Treatment
US20090035260A1 (en) * 2002-07-29 2009-02-05 Therapicon Srl Enhanced nasal composition of active peptide
WO2004084859A2 (en) * 2003-03-21 2004-10-07 Nastech Pharmaceutical Company Inc. Nasal calcitonin formulations containing chlorobutanol
AU2004235744A1 (en) * 2003-05-01 2004-11-18 Archimedes Development Limited Nasal administration of the LH-RH analog leuprolide
AR044852A1 (es) 2003-06-24 2005-10-05 Novartis Ag Una composicion farmaceutica para la administracion parenteral que comprende un analogo de somatostatina
ITMI20040235A1 (it) * 2004-02-13 2004-05-13 Therapicon Srl Preparazione farmaceutica per il cavo orale
EA016274B1 (ru) * 2007-08-02 2012-03-30 Игорь Анатольевич Помыткин Применение янтарной кислоты для профилактики и лечения нейродегенеративных заболеваний
CN108195965B (zh) 2011-06-07 2021-02-23 旭化成制药株式会社 含pth肽冷冻干燥制剂的检査方法及包含该含pth肽冷冻干燥制剂的医药品的制造方法
PE20171334A1 (es) 2015-02-17 2017-09-13 Lilly Co Eli Formulacion en polvo nasal para el tratamiento de hipoglicemia
US20180243224A1 (en) * 2015-08-19 2018-08-30 Vivus, Inc. Pharmaceutical formulations
WO2019102310A1 (en) * 2017-11-24 2019-05-31 Alaval (Pty) Ltd Vip formulation for management of inflammatory conditions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55153712A (en) * 1979-05-18 1980-11-29 Kao Corp Insulin pharmaceutical preparation and its production
JPS6034925B2 (ja) * 1979-07-31 1985-08-12 帝人株式会社 持続性鼻腔用製剤およびその製造法
JPS5885813A (ja) * 1981-11-17 1983-05-23 Toyo Jozo Co Ltd 吸収性良好な製剤
JPS57188526A (en) * 1981-05-14 1982-11-19 Takeda Chem Ind Ltd Peptide-containing pharmaceutical preparation
US4476116A (en) * 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
EP0187433B1 (de) * 1983-08-01 1990-12-27 Teijin Limited Pulverige pharmazeutische Zusammensetzung zur Anwendung auf die Schleimhaut der Mund- oder Nasenhöhle
JPS61267528A (ja) * 1984-11-26 1986-11-27 Yamanouchi Pharmaceut Co Ltd 吸収促進剤を含有するカルシトニン経鼻剤
JPS61194034A (ja) * 1985-02-25 1986-08-28 Teijin Ltd 経鼻投与用粉末状組成物

Also Published As

Publication number Publication date
US5059587A (en) 1991-10-22
EP0302772A1 (de) 1989-02-08
KR890003400A (ko) 1989-04-14
DE3875025T2 (de) 1993-06-24
EP0302772B1 (de) 1992-09-30

Similar Documents

Publication Publication Date Title
DE3875025T2 (de) Calcitonin enthaltende zusammensetzung fuer die nasale verabreichung.
DK453585A (da) Laegemiddel-indgivelsessystem
IT8619625A0 (it) Composizioni farmaceutiche per inalazione.
ZA857355B (en) Novel drug delivery system
GB2100605B (en) Bandage for administering drugs.
IT1219402B (it) Dispensatore di farmaci
ZA917528B (en) Nasal pharmaceutical composition.
GB8502156D0 (en) Drug delivery
PT80525A (en) Sustained release drug delivery device
NO162056C (no) Innretning for medisinavlevering.
NO882897D0 (no) Avleveringssystem for legemidler.
IT1214683B (it) Composizioni farmaceutiche nasali
GB2193891B (en) Nasal pharmaceutical composition containing a somatostatin anologue.
DE3382112D1 (de) Pharmazeutische zusammensetzung.
IT1219401B (it) Dispensatore di farmaci
FI883673A0 (fi) Farmaceutiska kompositioner.
IT1213453B (it) Composizione farmaceutica.
DE3865818D1 (de) Arzneizubereitung fuer inhalatorische anwendungen.
IT8722647A0 (it) Composizione farmaceutica per somministrazione nasale.
DE3667915D1 (de) Pharmazeutische zusammensetzung.
IE873499L (en) Calcitonin compositions for nasal administration
IT1215261B (it) Composizioni farmaceutiche adattivita' antigalattopoietica.
IT8224219A0 (it) Composizione farmaceutica per la somministrazione orale di calcitonina.
IT8819541A0 (it) Composizione farmaceutica per somministrazione nasale.
IT8323911A0 (it) Composizione farmaceutica per la somministrazione orale di calcitonina.

Legal Events

Date Code Title Description
8380 Miscellaneous part iii

Free format text: DER PATENTINHABER LAUTET RICHTIG: ASAHI KASEI KOGYO K.K., OSAKA, JP

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee